Myriad Genetics Valuation
| MYGN Stock | USD 9.91 0.02 0.20% |
At this time, the firm appears to be overvalued. Myriad Genetics secures a last-minute Real Value of $9.33 per share. The latest price of the firm is $9.91. Our model forecasts the value of Myriad Genetics from analyzing the firm fundamentals such as Current Valuation of 944.6 M, return on equity of -0.17, and Profit Margin of (0.15) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Myriad Genetics' valuation include:
Price Book 1.2933 | Enterprise Value | Enterprise Value Ebitda (23.47) | Price Sales 1.0825 | Forward PE 126.5823 |
Overvalued
Today
Please note that Myriad Genetics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Myriad Genetics is based on 3 months time horizon. Increasing Myriad Genetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Myriad Genetics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Myriad Stock. However, Myriad Genetics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.91 | Real 9.33 | Target 21.2 | Hype 9.93 | Naive 11.28 |
The intrinsic value of Myriad Genetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Myriad Genetics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Myriad Genetics helps investors to forecast how Myriad stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Myriad Genetics more accurately as focusing exclusively on Myriad Genetics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Myriad Genetics' intrinsic value based on its ongoing forecasts of Myriad Genetics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Myriad Genetics' closest peers.
Myriad Genetics Cash |
|
Myriad Valuation Trend
Knowing Myriad Genetics' actual value is paramount for traders when making sound investment determinations. Using both Myriad Genetics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Myriad Revenue by Product
Myriad Genetics Total Value Analysis
Myriad Genetics is now forecasted to have valuation of 944.6 M with market capitalization of 906.7 M, debt of 326.5 M, and cash on hands of 205.1 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Myriad Genetics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
944.6 M | 906.7 M | 326.5 M | 205.1 M |
Myriad Genetics Investor Information
About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.29. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Myriad Genetics has Price/Earnings To Growth (PEG) ratio of 1.4. The entity recorded a loss per share of 1.41. The firm had not issued any dividends in recent years. Myriad Genetics had 2:1 split on the 26th of March 2009. Based on the key indicators related to Myriad Genetics' liquidity, profitability, solvency, and operating efficiency, Myriad Genetics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Myriad Genetics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Myriad Genetics has an asset utilization ratio of 81.51 percent. This suggests that the Company is making $0.82 for each dollar of assets. An increasing asset utilization means that Myriad Genetics is more efficient with each dollar of assets it utilizes for everyday operations.Myriad Genetics Ownership Allocation
The majority of Myriad Genetics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Myriad Genetics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Myriad Genetics. Please pay attention to any change in the institutional holdings of Myriad Genetics as this could imply that something significant has changed or is about to change at the company.Myriad Genetics Profitability Analysis
The company reported the previous year's revenue of 837.6 M. Net Loss for the year was (127.3 M) with profit before overhead, payroll, taxes, and interest of 585.4 M.About Myriad Genetics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Myriad Genetics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Myriad Genetics based exclusively on its fundamental and basic technical indicators. By analyzing Myriad Genetics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Myriad Genetics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Myriad Genetics. We calculate exposure to Myriad Genetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Myriad Genetics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 585.4 M | 338.4 M | |
| Pretax Profit Margin | (0.31) | (0.30) | |
| Operating Profit Margin | (0.31) | (0.29) | |
| Net Loss | (0.31) | (0.30) | |
| Gross Profit Margin | 0.79 | 0.94 |
Myriad Genetics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 91.3 M | |
| Forward Price Earnings | 126.5823 |
Myriad Genetics Current Valuation Indicators
Myriad Genetics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Myriad Genetics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Myriad Genetics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Myriad Genetics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Myriad Genetics' worth.When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Revenue Per Share | Quarterly Revenue Growth 0.071 | Return On Assets | Return On Equity |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.